Results 31 to 40 of about 498,041 (267)

Integrated Technology Platform Protein Kinases for Drug Development in Oncology

BioTechniques, 2002
Protein kinases are among the most promising targets for drug discovery and development, mostly in oncology but also in other fields such as inflammation, Alzheimer's, and infectious diseases.
Christoph Sachsenmaier, Christoph Schäechtele   +1 more
doaj   +1 more source

Protein Kinase Inhibitors

Folia Biologica, 2006
Since protein kinases have been found to be implicated in many diseases, first of all malignancies, they are considered as promising therapeutic targets. Many protein kinase inhibitors have been designed by now. These molecules have a low molecular weight and most of them bind to protein kinases competing with ATP for the ATP-binding site. Some protein
I, Shchemelinin, L, Sefc, E, Necas
openaire   +2 more sources

Metabolic Kinases Moonlighting as Protein Kinases [PDF]

Trends in Biochemical Sciences, 2018
Protein kinases regulate every aspect of cellular activity, whereas metabolic enzymes are responsible for energy production and catabolic and anabolic processes. Emerging evidence demonstrates that some metabolic enzymes, such as pyruvate kinase M2 (PKM2), phosphoglycerate kinase 1 (PGK1), ketohexokinase (KHK) isoform A (KHK-A), hexokinase (HK), and ...
Zhimin, Lu, Tony, Hunter
openaire   +2 more sources

Role of protein phosphorylation in cell signaling, disease, and the intervention therapy

MedComm, 2022
Protein phosphorylation is an important post‐transcriptional modification involving an extremely wide range of intracellular signaling transduction pathways, making it an important therapeutic target for disease intervention.
Kun Pang, Wei Wang, Jia‐Xin Qin, Zhen‐Duo Shi, Lin Hao, Yu‐Yang Ma, Hao Xu, Zhuo‐Xun Wu, Deng Pan, Zhe‐Sheng Chen, Cong‐Hui Han   +10 more
doaj   +1 more source

Roscovitine Targets, Protein Kinases and Pyridoxal Kinase [PDF]

Journal of Biological Chemistry, 2005
(R)-Roscovitine (CYC202) is often referred to as a "selective inhibitor of cyclin-dependent kinases." Besides its use as a biological tool in cell cycle, neuronal functions, and apoptosis studies, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, viral infections, and glomerulonephritis.
Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., S. P., Coburn, Tang, L., Jiang, T., D. C., Liang, Galons, H., J. F., Dierick, L. A., Pinna, Meggio, F., Totzke, F., Schachtele, C., Lerman, A. S., Carnero, A., Wan, Y., Gray, N., Meijer, L.   +21 more
openaire   +5 more sources

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson, Ingrid Winship, Gary Hammerschlag, Laura Scardamaglia   +3 more
wiley   +1 more source

Comparative analysis of protein kinases and associated domains between Ascomycota and Basidiomycota

Journal of Integrative Agriculture, 2019
Protein kinases play an important role in every aspect of cellular life. In this study, we systemically identified protein kinases from the predicted proteomes of 59 representative fungi from Ascomycota and Basidiomycota.
Guo-liang PEI, Jun GUO, Qin-hu WANG, Zhen-sheng KANG   +3 more
doaj   +1 more source

Deactivatable Bisubstrate Inhibitors of Protein Kinases

Molecules, 2022
Bivalent ligands, including bisubstrate inhibitors, are conjugates of pharmacophores, which simultaneously target two binding sites of the biomolecule. Such structures offer attainable means for the development of compounds whose ability to bind to the ...
Tanel Sõrmus, Darja Lavogina, Erki Enkvist, Asko Uri, Kaido Viht   +4 more
doaj   +1 more source

NRASQ61R Expression in Lymphatic Endothelial Cells Causes Enlarged Vessels, Hemorrhagic Chylous Effusions, and High Mortality in a Mouse Model of Kaposiform Lymphangiomatosis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Kaposiform lymphangiomatosis (KLA) is an aggressive complex lymphatic anomaly. Patients exhibit malformed lymphatic vessels and often develop hemorrhagic effusions and elevated angiopoietin‐2 (Ang‐2) levels. A somatic NRAS p.Q61R (NRASQ61R) mutation has been associated with KLA.
C. Griffin McDaniel, Patricia Pastura, Joshua P. Scallan, Timothy D. Le Cras   +3 more
wiley   +1 more source

Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors

Cells
Protein kinases have essential responsibilities in controlling several cellular processes, and their abnormal regulation is strongly related to the development of cancer.
Mohammed Hawash
doaj   +1 more source